$SYK

Fletcher Robert S sold $328K of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 1,067 shares of STRYKER CORP (SYK) at $307.30 ($0.33M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
high confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

Because the plan is pre-arranged, the disclosure usually has limited incremental information content for valuation or near-term fundamentals.

02

Market read

Traders may monitor for patterns in insider activity, but this single 10b5-1 sale is unlikely to drive a sustained repricing.

03

What to watch

The transaction is explicitly pre-arranged (10b5-1), and the filing date may not reflect when the market reacts; execution occurred 2026-05-28.

Relevance 4/10Novelty 2/10Timing: Filed today; sale executed on 2026-05-28 under a 10b5-1 plan.

Background

SEC Form 4 reports insider trades; this one is an officer (VP, Chief Legal Officer) open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$SYKNeutralHigh confidence
Context

Stryker (SYK) disclosed an officer open-market sale of 1,067 shares at ~$307.30 via a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal; any effect would be short-lived unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with explicit 10b5-1 pre-arrangement, reducing the likelihood of new, information-driven signaling.

Market effects

No clear sector read-through; this is a single-company insider transaction without guidance/operational changes.

None.

None.

Counterpoint

Even with 10b5-1, repeated or unusually large sales can be interpreted by some traders as confidence erosion—though this specific sale size is modest.

Key entities

  • STRYKER CORP

    Subject of the insider transaction disclosure (officer sale under 10b5-1).

  • Fletcher Robert S

    VP, Chief Legal Officer who sold 1,067 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.